Kairos Pharma Ltd. Participation in H.C. Wainwright Global Investment Conference FAQ

What is Kairos Pharma Ltd. presenting at the H.C. Wainwright Global Investment Conference?

Kairos Pharma Ltd. will present its advancements in cancer therapeutics, including its lead candidate ENV105, which targets CD105 to overcome drug resistance in cancer, at the H.C. Wainwright 27th Annual Global Investment Conference.

When and where is the H.C. Wainwright Global Investment Conference taking place?

The conference is scheduled for September 8–10, 2025, at the Lotte New York Palace Hotel in New York City.

How can I view Kairos Pharma Ltd.’s presentation at the conference?

The presentation will be available virtually via kairospharma.com.

What is ENV105 and what does it target?

ENV105 is Kairos Pharma Ltd.’s lead candidate, an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments, aiming to reverse drug resistance and restore the effectiveness of standard therapies.

What are the current clinical trials for ENV105?

ENV105 is currently in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer.

Where can I find more information about Kairos Pharma Ltd.?

More information is available on the company’s website at www.KairosPharma.com and the latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA.

What is the significance of Kairos Pharma Ltd.’s participation in the conference?

Participation in the conference provides Kairos Pharma Ltd. with a platform to showcase its innovative cancer therapeutics to investors and the investment community, potentially attracting further interest and investment in its research and development efforts.

Who can attend the H.C. Wainwright Global Investment Conference?

The conference is aimed at the investment community, including investors, analysts, and other stakeholders interested in the latest developments in the biopharma and other sectors.

What is InvestorWire and how is it related to Kairos Pharma Ltd.?

InvestorWire is a specialized communications platform that provides advanced wire-grade press release syndication for companies like Kairos Pharma Ltd., helping them reach a wide audience of investors and the general public.